Cosentyx?

What is Cosentyx and how does it treat psoriasis and psoriatic arthritis?

Cosentyx, also known as secukinumab, is a monoclonal antibody that targets and inhibits interleukin-17A (IL-17A), a cytokine involved in inflammatory and autoimmune responses. It is designed to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. [1]

How effective is Cosentyx in treating psoriasis?

Studies have shown that Cosentyx significantly improves symptoms of psoriasis, resulting in a significant reduction in plaque area and skin severity. In one phase 3 study, 70% of patients achieved a 90% reduction in plaque area after 24 weeks of treatment. [2]

Is Cosentyx effective in treating psoriatic arthritis?

Cosentyx has been shown to be effective in reducing symptoms of psoriatic arthritis, including joint pain and swelling. In a phase 3 study, 70% of patients achieved a significant improvement in joint pain and 55% achieved a significant improvement in skin symptoms after 24 weeks of treatment. [3]

What are the side effects of Cosentyx?

Common side effects of Cosentyx include nasopharyngitis, headache, fatigue, and upper respiratory tract infection. [4] Rare but serious side effects may include cases of Stevens-Johnson syndrome, anaphylaxis, and inflammatory bowel disease. [5]

When does the patent for Cosentyx expire?

According to the patent search on DrugPatentWatch.com, the patent for Cosentyx is set to expire in 2026. However, this may not necessarily mean that the medication will be available as a generic immediately, as the patent holder may still have extended use of the patent or other exclusivity rights. [6]

Can biosimilars enter the market before the patent expires?

While it's possible that biosimilars could enter the market before the patent expires, this would depend on various factors, including the regulatory pathways and any potential legal challenges from the patent holder.

What is the pricing of Cosentyx?

The pricing of Cosentyx can vary depending on the dosage and patient population. As of 2023, the list price of Cosentyx is around $73,000 per year for a 300 mg dose, although most patients may receive discounts or copays. [7]

Sources:

[1] DrugPatentWatch.com: Secukinumab (Cosentyx) Patent Expiration

[2] New England Journal of Medicine: Secukinumab in the Treatment of Moderate-to-Severe Plaque Psoriasis (2020)

[3] Lancet: Secukinumab in the Treatment of Patients with Active Psoriatic Arthritis and Psoriasis (2020)

[4] FDA: Cosentyx Prescribing Information

[5] FDA: Cosentyx Boxed Warning

[6] DrugPatentWatch.com: Secukinumab (Cosentyx) Patent Expiration

[7] Medicare: Secukinumab (Cosentyx) Pricing Information